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Abstract
We propose a novel framework to analyse the macroeconomic impact of non-
communicable diseases. We incorporate measures of disease prevalence into a human
capital augmented production function, which enables us to determine the economic
costs of chronic health conditions in terms of foregone gross domestic product (GDP).
Unlike previously adopted frameworks, this approach allows us to account for i) varia-
tions in human capital for workers in different age groups, ii) mortality and morbidity
effects of non-communicable diseases, and iii) the treatment costs of diseases. We ap-
ply our methodology to China, Japan, and South Korea, and estimate the economic
burden of chronic conditions in five domains (cardiovascular diseases, cancer, respira-
tory diseases, diabetes, and mental health conditions). Overall, total losses associated
with these non-communicable diseases over the period 2010-2030 are $16 trillion for
China (measured in real USD with the base year 2010), $5.7 trillion for Japan, and
$1.5 trillion for South Korea. Our results also highlight the limits of cost-effectiveness
analysis by identifying some intervention strategies to reduce disease prevalence in
China that are cost beneficial and therefore a rational use of resources, though they
are not cost-effective as judged by conventional thresholds.
JEL Classification: H51, I15, I18, J24, O11.
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1 Introduction
Globally, non-communicable diseases (NCDs) result in 65% of all deaths (Lozano et al.,
2011) and 54% of all healthy life years lost as measured by DALYs (disability-adjusted life
years) (Murray et al., 2013). Apart from the enormous burden of pain and suffering that
these conditions impose, the global economic burden of non-communicable diseases has
been estimated to be in the region of $47 trillion during 2010 through 2030 (measured in
real USD with the base year being 2010, or 75% of global GDP in 2010; see Bloom et al.,
2012). Moreover, the prevalence of chronic conditions, specifically non-communicable
diseases such as cardiovascular diseases, cancer, respiratory diseases, diabetes, and mental
health conditions, is likely to rise substantially over the coming decades (Kearney et al.,
2005).
This phenomenon is likely to affect not only developed countries but also low- and middle-
income countries as a result of changes in modifiable risk factors (such as smoking, dietary,
and exercise patterns) and non-modifiable risk factors (such as population ageing). One
important factor that drives chronic disease prevalence worldwide is changing lifestyle
patterns shifting daily living toward more sedentary occupations and less healthy diets.
Urbanization has many economic benefits in terms of returns to agglomeration, specializa-
tion, and efficiency, but it can also negatively affect population health through mechanisms
such as diffusion of risky behaviour and exposure to pollution. For example, an important
difference in risk factor trajectories between low- and middle-income countries and high-
income countries is the divergence in smoking patterns. While cigarette and tobacco con-
sumption has been falling in many high-income countries, smoking has been rising in India
and China. Given that tobacco consumption is the most important risk factor for many
non-communicable diseases, this is likely to raise the prevalence of non-communicable dis-
eases in those countries. Another difference between developed and developing countries
is that the former have been quite successful at minimising the risk of death associated
with communicable diseases, whereas communicable diseases remain a major contributor
to mortality in low-income countries. This implies that low-income countries often face a
double burden of disease.
In developed countries, population ageing is an inexorable consequence of fertility and mor-
tality patterns. Many high-income countries already face rapid demographic change, and
because chronic conditions tend to increase with age, the proportion of their populations
affected by non-communicable diseases will rise. Likewise, many emerging economies are
either already experiencing population ageing or will do so in the near future. Particularly
interesting cases for studying the effects of ageing-related increases in non-communicable
disease prevalence are Japan, because it has the largest share of older people globally, and
China and South Korea because they are experiencing very rapid population ageing. The
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main goals of this paper are to estimate and project the economic burden of chronic con-
ditions for these three countries until 2030 and to compare the challenges these countries
face in terms of non-communicable disease impact.
Through several pathways, disease burden is expected to affect economic outcomes in
general and economic growth in particular. First, chronic conditions reduce the supply
of labour through mortality, early retirement (Dwyer and Mitchell, 1999; Lindeboom and
Kerkhofs, 2009; Jones et al., 2010), and reduced productivity (Lo´pez-Casasnovas et al.,
2005; Ja¨ckle and Himmler, 2010). In addition, individuals may alter their employment
behaviour because they anticipate or fear the future onset of illness and negative effects
of health conditions (McGarry, 2004).1 Second, current interventions related to NCDs
(including medical treatment and prevention) require a substantial amount of resources,
part of which could otherwise be used for other productive activities. Therefore, NCDs
reduce the net availability of government funds and impede the accumulation of physi-
cal and human capital by, for example, diverting investment from important areas such
as education and infrastructure. Additionally, reduced productivity together with lower
labour supply leads to a decline in aggregate income and therefore further reduce savings
and investment. Our model addresses these pathways and is summarized in Figure 1.
Overall, the global burden associated with non-communicable diseases can be expected
to grow in magnitude. While a substantial literature describes the micro-level effects of
health conditions such as cancer on economic and overall well-being, less evidence exists
on how chronic conditions interact to affect aggregate outcomes in the population as a
whole. The aggregate view is typically absent from studies of the individual-level effects of
non-communicable diseases because capturing spillover effects and externalities is difficult
where the health status of one person affects the well-being of another individual or group
of individuals.
The economic impact of health conditions in general, and non-communicable diseases in
particular, is of special importance and interest to policymakers. Faced with increases
in the prevalence of chronic conditions, governments and other stakeholders may wish
to enact policies that are effective at reducing disease incidence and its consequences.
Several possible interventions can reduce the prevalence of non-communicable diseases.
For example, a series of “best-buy” investments has been proposed because they are cost-
effective and easy to implement within the constraints of low- and middle-income countries.
These policies include increasing taxes on alcohol and tobacco use, reducing salt intake in
food, and replacing trans fats with polyunsaturated fats (Bloom et al., 2011).
However, establishing whether particular programs are worthy of investment can be diffi-
1For a theoretical analysis of the interrelationship between health and retirement behaviour, see Bloom
et al. (2007, 2014d). Building on this, Prettner and Canning (2014) explore the macroeconomic implica-
tions, and Kuhn et al. (2015) study the interaction between health and retirement behaviour.
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Figure 1: Summary of Pathways from NCDs to Economic Growth
cult without a thorough assessment of the economic benefits of these interventions and a
summary of the potential returns on investment for different policy options. This is par-
ticularly the case for many candidate policies, not just in the health domain, but also in
relation to other sectors such as targeting improvements in infrastructure and education,
or when other health conditions such as communicable diseases remain highly prevalent.
In addition, policymakers and the public may be unaware of the impact of these condi-
tions, particularly on labour markets and on capital accumulation. A thorough assessment
of the economic impact of non-communicable diseases will therefore provide evidence on
which types of policies are viable and establish whether investments in health in general,
and chronic conditions in particular, are likely to provide returns on investment sufficient
to justify their implementation. In sum, accurate estimates of the economic burden of
non-communicable diseases are important for providing a cost-benefit analysis of alterna-
tive interventions and for ranking alternative policy strategies in terms of their return on
investment.
Approaches to estimating the economic effects of health conditions include the cost of
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illness method, where the direct costs associated with a disease are calculated; the value
of a statistical life (VSL) approach, where costs are inferred from willingness to pay stud-
ies or observed avoidance behaviour for risky occupations or scenarios; econometric esti-
mates taken from cross-country growth regressions; and macroeconomic models (such as
a production function-based approach or a general-equilibrium framework), where output
trajectories for different scenarios are simulated. Each approach has advantages and dis-
advantages. In our paper, we aim to account for the aggregate effects on output when
estimating the full economic impact of non-communicable diseases. Therefore, we adopt a
macroeconomic approach that incorporates disease prevalence into a human capital aug-
mented production function. In this way, we can model the effects of chronic conditions
on aggregate effective labour supply and on capital accumulation in a flexible framework
that can be used to characterize an extensive set of pathways through which health affects
the economy.2
Our main contribution is to modify and extend the model that Abegunde and Stanci-
ole (2006) first used to examine the impact of non-communicable diseases on economic
growth. The original formulation of the basic approach, which was named the EPIC (or
Projecting the Economic Cost of Ill Health) tool, relied on the Solow (1956) framework
and was designed by the World Health Organization (WHO).3 Altogether, we propose
a novel framework that builds upon the WHO EPIC tool, but additionally considers i)
heterogeneous human capital levels of workers in different age groups, ii) that NCDs and
health conditions not only lead to mortality but also to morbidity, and iii) the effect of
treatment costs on capital accumulation.
While our analysis focuses on NCDs, the framework we develop here is quite general and
could easily apply to other health domains, such as communicable diseases, road traffic
accidents, and tobacco control. We focus on chronic conditions for several reasons. First,
the data requirements to implement the model for the four NCDs that are the focus of the
United Nations (cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes)
and mental health conditions are already quite substantial, and extending the model in this
paper to include other health conditions would result in a very lengthy exposition. Second,
the countries we consider (China, Japan, and South Korea) are either middle- or high-
income countries that have made great strides in dealing with communicable diseases.
However, NCDs have been relatively neglected from a public health point of view in
these countries, and unlike communicable diseases, the prevalence of chronic conditions
is expected to rise substantially over the coming decades. Finally, we are interested in
assessing the economic impact of population ageing via changes in the health status of
2See Kuhn and Prettner (2016) for an analysis of the impact of health care on economic growth and
welfare within a Blanchard-Romer style general equilibrium model, in which they take account both of
morbidity and mortality related channels.
3The basic EPIC model has been used to estimate the economic burden of chronic conditions in India,
China, Indonesia, and worldwide (cf. Bloom et al., 2012, 2014a,b, 2015).
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the population, and because age is an important non-modifiable risk factor for NCDs, we
believe that focusing on these conditions is desirable. Nevertheless, we hope to extend the
model to other aspects of health in future research.
The paper is organized as follows. Section 2 compares the four most popular methods
used to assess the economic burden of different diseases and discusses their advantages and
disadvantages. Section 3 proposes a novel framework that builds upon the WHO EPIC
tool but additionally considers heterogeneous human capital levels of workers in different
age groups, the morbidity effect of NCDs, and the effect of treatment costs on capital
accumulation. Section 4 implements the model for China, Japan, and South Korea and
presents the results for these three countries. Section 5 summarizes and draws conclusions.
2 Comparison of methods to assess the economic burden of
diseases
This section describes the main approaches used to quantify the economic impact of health
conditions, focusing on the advantages and disadvantages of each framework. We start
with the cost of illness (COI) approach, which is a simple and easy-to-understand method
that summarizes the burden of a certain disease over a particular time period in a single
number. This number is defined as the sum of all personal medical care costs (e.g., inpa-
tient and outpatient hospital costs); personal non-medical care costs (e.g., transportation
and relocation expenses); non-personal costs (e.g., for research activities); and loss of in-
come due to absenteeism, early retirement, or premature death. Altogether, the medical
costs, the non-medical costs, and the research costs are referred to as direct costs, while
the loss of income is referred to as an indirect cost.4 The advantage of this method is that
the outcome is easily interpreted as the monetary value of the resources that could be
saved by avoiding a particular disease. The main drawbacks are that no economic adjust-
ment mechanisms are considered (e.g., the substitution of labour lost due to an illness by
capital or other workers) and that COI studies disregard the effect of diseases on physical
capital and human capital accumulation (for a general debate on the usefulness of the COI
approach see Currie et al., 2000; Rice, 2000; World Health Organization, 2009).
An alternative way to estimate the costs of health conditions is to reconstruct a person’s
implicit valuation of his/her own life, the value of a statistical life, by estimating a person’s
willingness to accept premia for risky occupations via wage regressions, or by estimating a
person’s willingness to pay for the reduction of risks via hedonic price regressions (Viscusi
and Aldy, 2003). The monetary value that a person assigns to his/her own life can be
inferred from the parameter estimates in these regressions. The main advantage of this
4Most studies of the costs of NCDs rely on this approach (as an example, see Beaulieu et al., 2009).
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approach is that it also delivers a single number that, if multiplied by the number of cases,
can be interpreted as the total statistical value of the loss due to an illness. While the COI
approach focuses more on the objective costs of an illness, the VSL approach also implicitly
covers the costs of pain and suffering via the revealed preferences of the consumers/workers
who are studied. Prominent studies by Murphy and Topel (2006) and Lakdawalla et al.
(2010) apply the VSL methodology to calculate the value of advances against cardiac
disease and cancer. The main drawback is that the VSL approach yields an estimate of
the statistical loss due to an illness that strongly depends on the age and the income level of
workers. Consequently, the estimates vary widely among different countries. Furthermore,
economic adjustment mechanisms are again not taken into consideration.5
Another method to assess the economic costs of an illness is to estimate a cross-country
growth regression in the vein of Barro (1991) and Islam (1995), in which the main re-
gressors of interest contain the prevalence of the illness under consideration. From the
parameter estimate associated with the prevalence of an illness, its impact on growth can
be inferred directly (see Suhrcke and Urban, 2010, for estimates of the negative growth
effect of cardiovascular diseases). The advantage of this approach is that, when the regres-
sion is appropriately specified, the estimated growth effect is readily apparent from the
final result, which already incorporates economic adjustment mechanisms. Consequently,
this method overcomes one of the crucial shortcomings of the COI and VSL approaches.
However, growth regressions are very data intensive, requiring a wide range of precisely
measured control variables for all countries in the sample (see Durlauf et al., 2005; Eber-
hardt and Teal, 2011; Sala-i Martin et al., 2004; Sala-i Martin, 1997, for discussions).
Furthermore, the result is an average of the growth effect over all countries included in
the regression, which does not account for specific country characteristics and potential
heterogeneity in the impact of chronic conditions across countries. Additionally, this ap-
proach only allows for an assessment of severe diseases that affect many people (such
as cardiovascular diseases). Detecting a significant growth effect for less severe diseases
that do not affect many people is difficult given the small sample sizes that typically con-
front growth regressions (cf. Durlauf et al., 2005). Finally, attempts to deal with reverse
causality and omitted variable bias are contentious in the literature (Weil, 2014).
Abegunde and Stanciole (2006) and the WHO first proposed the EPIC framework, which
simulates a Solow (1956) growth model that considers the adverse effects of diseases on
physical capital accumulation and on labour supply. Bloom et al. (2012, 2014a,b, 2015)
have applied this framework to several developed and less developed countries. While the
EPIC approach accounts for the fact that physical capital or other workers can replace
lost labour and therefore allows for economic adjustment mechanisms, it only considers
mortality and not morbidity. Furthermore, it does not accurately account for the cost of
5See Frankovic et al. (2016) for a theoretical analysis of how the VSL responds to exogenous medical
progress in general equilibrium.
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treatments and for the fact that different age groups of workers have, in general, different
productivity levels because of their different schooling intensity and experience patterns.
This is, however, important because of the relative concentration of chronic conditions
among older age groups.
Our contribution focuses on these three shortcomings of the EPIC model and proposes
a novel framework that builds upon the Lucas (1988) production function. In so doing,
we explicitly allow different age groups of workers to have different education levels and
different levels of experience, and we address the lack of a morbidity mechanism by in-
corporating information on disease morbidity, as measured by DALYs reported by the
Institute for Health Metrics and Evaluation (2013). Furthermore, we account for the
treatment costs of diseases.
The production function-based framework we use also has some limitations. First, it is not
a general equilibrium model in the sense that all decisions are microfounded. For example,
individuals who live longer because the prevalence of a disease is reduced might invest more
in education or they might save more. While implementing a general equilibrium structure
would be highly complex and would require other restrictive assumptions to be tractable,
disregarding the mentioned general equilibrium repercussions implies that our estimates
of the economic burden of NCDs are conservative. Another issue with the production
function-based framework is that we consider the impact of health on growth, but do not
model a channel linking growth to health.6 Incorporating a channel reflecting an effect
of economic growth on health would be arbitrary in the absence of good evidence on the
causal pathways of interest and would introduce additional complexity into the model.
Nevertheless, abstracting from a feedback effect of economic growth on health clearly
implies that the economic burden of NCDs that we calculate is likely to be a lower bound
for the true costs.
3 The model
We aim to quantify the economic burden of a particular disease, which requires us to
compare economic performance between two scenarios: a status quo scenario, in which
GDP is projected to grow based on current estimates and projections of disease prevalence,
and a counterfactual scenario, in which the disease prevalence is eliminated from the
beginning of the time period. We define the overall economic impact of the relevant
6The nature of the relationship between health and growth and the potential for reverse causality has
been debated extensively in both the macroeconomics and microeconomics literature (see, for example,
Acemoglu and Johnson, 2007, 2014; Aghion et al., 2011; Bloom et al., 2004, 2014c; Cervellati and Sunde,
2011; Cutler et al., 2006; Pritchett and Summers, 1996; Weil, 2007, 2014). While health and income
are typically highly correlated, the precise nature of the relationship remains controversial because of the
difficulties associated with identifying the causal effects of interest.
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disease as the cumulative difference between status quo GDP and counterfactual GDP in
each year (summed over the time period of interest). This framework is very flexible and
allows us to examine alternative scenarios in which GDP is calculated for a designated
percentage reduction in the prevalence of a specific disease. This allows us to analyse the
impact of a particular policy intervention, with the cost of the intervention factored into
a corresponding decrease in capital accumulation.
3.1 Human capital, physical capital, and aggregate output
Consider an economy populated by individuals of different age a in which time t ∈ [0,∞]
evolves discretely. Individuals of age group a are endowed with h
(a)
t units of human
capital and supply `
(a)
t units of labour from age 15 up to their retirement at age R, i.e., for
a ∈ [15, R]. Children below the age of 15 and retirees above the age of R do not work. At
the aggregate level are two production factors: physical capital (Kt) and human capital
(Ht). Human capital is defined as the aggregate age-specific effective labour supply
Ht =
R∑
a=15
h
(a)
t `
(a)
t N
(a)
t , (1)
where N
(a)
t denotes the number of individuals belonging to age group a. Note that aggre-
gate human capital is greater if more individuals of working age live in the economy (i.e.,
Nt =
∑R
a=15N
(a)
t is larger), if those individuals are endowed with more human capital
because they are either better educated or have more experience (i.e., h
(a)
t is higher for at
least one a), and if individuals in the economy supply more labour (i.e., `
(a)
t is higher for
at least one a).
Aggregate output Yt is used for three purposes: to pay treatment costs TCj,t
7 for disease
j ∈ I, where I is the set of diseases; to consume the quantity Ct; and to save. As a
consequence, physical capital (K) accumulates according to
Kt+1 = (1− δ)Kt + Yt − Ct −
∑
j∈I
TCj,t = (1− δ)Kt + stYt, (2)
where δ is the rate of depreciation and st refers to the savings rate. From Equation (2) it
follows that the savings rate is defined as
st = 1−
Ct +
∑
j∈I TCj,t
Yt
.
7These costs refer to the costs of ongoing treatment and of the intervention methods for the specific
disease. In general, these costs are best characterized by the direct costs of healthcare including hospital-
ization, medication, etc.
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Building upon Lucas (1988), aggregate output is given by the production function
Yt = AtK
α
t
(
R∑
a=15
h
(a)
t `
(a)
t N
(a)
t
)1−α
, (3)
where At is the technological level of the economy that evolves exogenously and α is
the elasticity of final output with respect to physical capital. The aggregate production
function takes into account that output is not only produced with physical capital and
raw labour as in the Solow (1956) framework on which the original EPIC model relies, but
with effective labour of which human capital is a central determinant.
We follow Mincer (1974) and construct average human capital of the cohort aged a ac-
cording to an exponential function of education and work experience:
h
(a)
t = exp
[
η1(ys
(a)
t,prim) + η2(ys
(a)
t,sec) + η3(ys
(a)
t,tert) + η4(a− 15)− η5(a− 15)2
]
, (4)
where η1 is the semi-elasticity of human capital with respect to years of primary education
as given by ys
(a)
t,prim, η2 is the semi-elasticity of human capital with respect to years of
secondary education as given by ys
(a)
t,sec, η3 is the semi-elasticity of human capital with
respect to years of tertiary education as given by ys
(a)
t,tert, and η4 and η5 are the semi-
elasticities of human capital with respect to the experience of the workforce (a−15) and the
experience of the workforce squared (a− 15)2, respectively. The values for the parameters
η1, η2, and η3 are taken from the studies by Hall and Jones (1999) and Psacharopoulos
(1994), while the values for η4 and η5 are taken from Heckman et al. (2006).
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Non-communicable diseases exert influence on the economy via three pathways: i) via
physical capital accumulation in the sense that savings finance part of the treatment
costs, reducing physical capital accumulation; ii) via effective labour supply in two ways:
first, disease-induced mortality reduces the population and hence the number of workers,
and second, the associated morbidity reduces individual productivity and increases absen-
teeism; and via the average human capital level because NCDs disproportionately affect
more experienced age groups.
3.2 Impact on physical capital accumulation
In the counterfactual scenario, we assume that a certain disease i ∈ I is eliminated, so the
treatment costs for disease i in Equation (2) are set to zero. Moreover, we define ICi,t to
be the cost for the intervention that helps eliminate this disease, whereas TCi,t refers to
8Note that another pathway exists, whereby a bad health condition affects human capital that we do
not account for by our specification: absenteeism due to bad health might lead to faster depreciation of
human capital because it sits idle.
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the treatment costs that would have been incurred without the elimination of the disease.
The accumulation of physical capital can then be written as
K¯t+1 = Y¯t − C¯t + (1− δ)K¯t −
∑
j∈I,j 6=i
TCj,t − ICi,t, (5)
where an overbar indicates that the corresponding variable refers to the counterfactual
scenario. Because the disease is assumed to be eliminated with a cost ICi,t, the resources
that were devoted to its treatment can now be used for savings or for consumption. Notice
that this creates an income effect that, in reality, could affect the division of households’
income between savings, and consumption. For tractability, we assume that, in the coun-
terfactual scenario, aggregate investment consists of two parts: a fixed share st of total
output and an additional part from (TCi,t − ICi,t) that would otherwise have been used
to pay for the treatment of disease i (after netting out the intervention cost):
I¯t = Y¯t − C¯t −
∑
j∈I,j 6=i
TCj,t = stY¯t + χ(TCi,t − ICi,t).
In this expression, χ is the fraction of the treatment cost that is diverted to savings and
we have the counterfactual savings rate
s¯t =
stY¯t + χ(TCi,t − ICi,t)
Y¯t
. (6)
As a result, the savings rate could increase if the treatment cost outweighed the interven-
tion cost.
3.3 Impact on labour supply
The evolution of labour supply in the status quo scenario is given by
L
(a)
t = N
(a)
t `
(a)
t with N
(a)
t =
[
1− σ(a−1)t−1
]
N
(a−1)
t−1 , (7)
where σ
(a)
t is the overall mortality rate of age group a. Denote the mortality rate of people
in age group a due to the disease i by σ
(a)
i,t and let σ
(a)
−i,t be the overall mortality rate due
to causes other than disease i. Then we simply have
(1− σ(a)t ) = (1− σ(a)i,t )(1− σ(a)−i,t).
Now we consider the mortality effect of disease i. In general, it reduces labour supply by
reducing the population N
(a)
t (through σ
(a)
i,t ). In the counterfactual case, where the disease
is eliminated from time t = 0 onward, the evolution of labour supply is defined similarly
to Equation (7), but with a different overall mortality rate (σ
(a)
−i,t instead of σ
(a)
t ). For
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simplicity, we assume that the number of births is the same in both cases at each point in
time t. In general, this is a good approximation because most NCDs affect older adults
who contribute little to overall fertility.
In the counterfactual scenario, the size of the cohort aged a at time t (N¯
(a)
t ) evolves
according to
N¯
(a)
t =
[
1− σ(a−1)−i,t−1
]
N¯
(a−1)
t−1 , N¯
(a)
0 = N
(a)
0 , N¯
(0)
t = N
(0)
t .
More specifically, if a > t, then this cohort was born before the elimination of disease i
such that
N¯
(a)
t =
[
1− σ(a−1)−i,t−1
] [
1− σ(a−2)−i,t−2
]
N¯
(a−2)
t−2 . . .
=
t−1∏
τ=0
[
1− σ(a−1−τ)−i,t−1−τ
]
N¯
(a−t)
0 =
t−1∏
τ=0
[
1− σ(a−1−τ)−i,t−1−τ
]
N
(a−t)
0 .
Notice that
N
(a)
t =
(t−1)∏
τ=0
[
1− σ(a−1−τ)t−1−τ
]
N
(a−t)
0 .
Hence, we have
N¯
(a)
t = N
(a)
t /
(t−1)∏
τ=0
[
1− σ(a−1−τ)i,t−1−τ
]
.
If a ≤ t, then this cohort was born after the elimination of disease i such that
N¯
(a)
t =
[
1− σ(a−1)−i,t−1
] [
1− σ(a−2)−i,t−2
]
N¯
(a−2)
t−2 . . .
=
a−1∏
τ=0
[
1− σ(a−1−τ)−i,t−1−τ
]
N¯
(0)
t−a =
a−1∏
τ=0
[
1− σ(a−1−τ)−i,t−1−τ
]
N
(0)
t−a.
Notice that
N
(a)
t =
(a−1)∏
τ=0
[
1− σ(a−1−τ)t−1−τ
]
N
(0)
t−a.
Hence, we have
N¯
(a)
t = N
(a)
t /
(a−1)∏
τ=0
[
1− σ(a−1−τ)i,t−1−τ
]
.
In sum, we arrive at the following equation:
N¯
(a)
t = N
(a)
t /
min{t,a}−1∏
τ=0
[
1− σ(a−1−τ)i,t−1−τ
]
, (8)
which accounts for the fact that the loss of labour due to mortality accumulates over the
years.
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The morbidity effect of the disease does not change the population size, but can affect the
labour participation rate because people with an illness typically reduce their labour supply
either by reducing working hours or by leaving the work force. Unlike the mortality effect,
tracing the accumulation of morbidity effects over time is complicated because people
affected by morbidity can be cured and hence increase their labour supply again in later
time periods. To capture this fact, we assume that, in each year, an ill person has a
probability (1− pi) of recovering from the disease. We assume that this probability stays
constant over time and that it is independent of the number of years the person lived with
the disease. The value of pi can then be easily inferred as the average duration of the
disease through
pi = 1− 1
duration of the disease
.
Because the impact of morbidity is hard to estimate directly, we first define
ξ
(a)
i =
loss of labour due to morbidity in age group a
loss of labour due to mortality in age group a
. (9)
Next, we assume that the following holds in any given year for age group a:
ξ
(a)
i =
Y LD
(a)
i
Y LL
(a)
i
, (10)
where Y LD
(a)
i represents the years lived with disease i and Y LL
(a)
i represents the years of
life lost due to disease i. Notice that ξ
(a)
i can be calculated from the corresponding DALY
data reported by the Institute for Health Metrics and Evaluation (2013).
Now consider a cohort aged a at time t, and let m
(a)
i be the rate of people leaving the
labour force due to morbidity of disease i. Then, if (10) is fulfilled, it is easy to see that
m
(a)
i = ξ
(a)
i σ
(a)
i,t .
Unlike labour supply, which can be derived recursively according to Equation (7), the
evolution of the labour participation rate is more complicated. People of different ages
have different labour participation rates, so a recursive framework cannot be adopted. For
tractability, we assume that the labour participation rate for people who are not affected
by disease i is exogenously given. Specifically, we define ˆ`t
(a)
to be the labour participation
rate of people without the disease. Because the morbidity effect drives workers out of the
labour force, the status quo labour participation rate is expected to be smaller than ˆ`t
(a)
.
Notice that the difference comes from two sources: newly affected people who leave the
labour force and people who left the labour force due to disease i years ago and have not
yet recovered. To fix the distortion caused by discretisation, we assume that i) at the
beginning of year t, the labour force `
(a)
t is calculated, and ii) at the end of each year,
13
morbidity effects are factored into the population.
Now we restrict our attention to the cohort aged a at time t. Notice that `
(a)
t is deter-
mined by i) the labour participation rate of “healthy” people ( ˆ`t
(a)
) and ii) the fraction
of “healthy” people at the beginning of year t (F (a)). Here, “healthy” means that the
person has not left the workforce due to morbidity, while the labour participation rate of
the “unhealthy” simply equals zero.
Proposition 1. For the cohort aged a at time t, the fraction of “healthy” people at the
beginning of year t can be approximated by
F (a) ≈
a−1∏
τ=0
[
1− pτim(a−1−τ)i
]
.
Proof. The case for a = 1 is trivial. We therefore prove the proposition by induction.
Suppose that
F (n) ≈
n−1∏
τ=0
[
1− pτim(n−1−τ)i
]
.
Then consider age n+ 1, where, with probability p, those who are sick at the beginning of
age n, (1 − F (n)), will still be sick, whereas the others return to the labour force. Then,
the disease will again claim a fraction m
(n)
i of the total “healthy” population each year.
Given that m
(n)
i for n = 1, . . . is small, we have
F (n+1) =
[
1− p(1− F (n))
]
(1−m(n)i )
≈
(
1− p{1−
n−1∏
τ=0
[
1− pτim(n−1−τ)i
]
}
)
(1−m(n)i )
≈
n∏
τ=0
(
1− pτim(n−τ)i
)
.
(11)
In this case, we assume that morbidity only affects the proportion of people in the labour
force and that it is completely independent of the mortality process.
Now we can write the approximate relationship between `
(a)
t and
ˆ`
t
(a)
as
`
(a)
t ≈ ˆ`t
(a)
F (a) = ˆ`t
(a)
a−1∏
τ=0
[
1− pτim(a−1−τ)i
]
. (12)
Although the closed-form solution can be obtained using induction, we prefer to use this
approximation for two reasons: first, the complexity is greatly reduced without sacrificing
much in the way of accuracy, and second, this approximation provides a very intuitive
interpretation and is directly comparable to Equation (8).
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The next step is to generate the labour participation rate of the counterfactual case (¯`
(a)
t )
from that of the status quo case (`
(a)
t ). Notice that here
¯`(a)
t is different from
ˆ`(a)
t . The
former represents the labour participation rate of the counterfactual case in which the
disease is eliminated from t = 0 onward; the latter is the labour participation rate of
“healthy” people. If a ≤ t, the cohort was born after the elimination of disease i and
hence we have ¯`
(a)
t =
ˆ`(a)
t (everyone is “healthy” in this cohort). If a > t, then the cohort
was born before the elimination of the disease. In this case, some members of the cohort
may have contracted the disease before t = 0 and not recovered yet. Knowing this, we
have the following:
¯`(a)
t =
ˆ`
t
(a)
, t ≥ a, (13)
¯`(a)
t ≈ ˆ`t
(a)
a−1∏
τ=t
[
1− pτim(a−1−τ)i
]
, t < a. (14)
Combining (12), (13), and (14), we get
¯`(a)
t ≈ `(a)t /
min{t,a}−1∏
τ=0
[
1− pτim(a−1−τ)i
]
= `
(a)
t /
min{t,a}−1∏
τ=0
[
1− pτi σ(a−1−τ)i,t−1−τ ξ(a−1−τ)i
]
. (15)
From Equation (15), we see that a larger pi leads to a lower participation rate, i.e., the
morbidity effect is more likely to accumulate over the years if the disease is hard to cure.
The intuition behind Equation (15) is the following: the different exposure to the disease
drives the difference between the labour participation rate of the status quo (`
(a)
t ) and
the counterfactual case (¯`
(a)
t ). For a ≤ t, the cohort in the counterfactual case avoided
exposure to the disease completely in the previous a years. For a > t, the cohort only
avoided exposure to the disease in the most recent t years.
Overall, the loss of labour supply in age group a at time t can be calculated as
∆L
(a)
t = L¯
(a)
t − L(a)t = `(a)t N (a)t
 1∏min{t,a}−1
τ=0
[
1− pτim(a−1−τ)i
] [
1− σ(a−1−τ)i,t−1−τ
] − 1

≈ `(a)t N (a)t
min{t,a}−1∑
τ=0
σ
(a−1−τ)
i,t−1−τ
[
1 + pτi ξ
(a−1−τ)
i
]
. (16)
The approximation in Equation (16) results from the observation that σ
(a)
i,t and ξ
(a)
i are
typically small numbers. Defining the term in curly brackets as M
(a)
i,t it follows that
∆L
(a)
t = L
(a)
t M
(a)
i,t . (17)
Intuitively, M
(a)
i,t can be interpreted as the cumulative labour supply impact of disease i
on the cohort aged a at time t.
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By plugging (17) into (1), the loss of human capital due to disease i at time t can be
written in percentage terms as
∆Ht
Ht
=
∑R
a=15 h
(a)
t `
(a)
t N
(a)
t M
(a)
i,t∑R
a=15 h
(a)
t `
(a)
t N
(a)
t
. (18)
Equation (18) implies that the human capital loss is related to the country’s demographic
structure. Even if the mortality and morbidity effects of a disease were similar in two
countries for each age group (similar M
(a)
i,t for both countries), the aggregate human capital
loss could still vary vastly due to the different weights (h
(a)
t `
(a)
t N
(a)
t ) on each age group.
Now, instead of completely eliminating the disease, suppose that the intervention only
reduces the disease prevalence by a certain percentage, say ρ. The previous discussion still
holds true, and we can obtain the loss of labour by replacing (σi,t,mi,t) with (ρσi,t, ρmi,t)
in (16). Denoting the loss of labour for age group a at time t in case of a reduction in the
disease prevalence by ρ as ∆L
(a)
t (ρ), it is easy to show that
∆L
(a)
t (ρ) ≈ `(a)t N (a)t
min{t,a}−1∑
τ=0
ρσ
(a−1−τ)
i,t−1−τ
[
1 + pτi ξ
(a−1−τ)
i
]
≈ ρL(a)t M (a)i,t ,
(19)
where M
(a)
i,t is defined in (17), and the approximation is valid when σi,t and mi,t are small.
Equation (19) shows that the cumulative loss of labour is approximately linear with respect
to disease prevalence averted (ρ) given that the mortality and morbidity of the disease are
small.
Our approach has the following advantages over the standard EPIC tool: first, we can
account for morbidity by adjusting the labour participation rate by disease based on the
data of the Institute for Health Metrics and Evaluation (2013); second, we can infer the
impact of a disease on physical capital accumulation by obtaining χ and TCi,t directly from
the data; and third, human capital accumulation is considered by employing a Mincerian
specification that allows for distinctions among primary, secondary, and tertiary education
and allows for the consideration of experience.
4 Results
We present direct estimates for five conditions for which the necessary mortality data
are available in EPIC (ischemic heart disease, cerebrovascular disease, diabetes, chronic
obstructive pulmonary disease (COPD), and breast cancer). The results are then scaled
up using Institute for Health Metrics and Evaluation (2013) data on DALYs to reflect
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the four NCDs that are the focus of the United Nations (cardiovascular diseases, cancer,
chronic respiratory diseases, and diabetes), plus mental health conditions. The scaling
is implemented by calculating the proportion of DALYs in a particular domain (e.g.,
cancer) that the relevant disease accounts for in EPIC (breast cancer in this instance).
If breast cancer accounts for 10% of the total DALYs lost to cancer, the scaling factor
applied to our results for breast cancer to obtain a result for all cancers is 0.1. Scaling
factors are calculated for each country. Similarly, we use WHO data on mental illness
DALYs to include estimates of economic losses from mental health conditions. The mental
health scaling factor is calculated by obtaining the ratio of DALYs accounted for by the
four NCD domains to the DALYs accounted for by mental health conditions. Obtaining
comprehensive information on the treatment costs associated with each disease is difficult.
As Table A1 shows, we calculated treatment costs from various sources. For the missing
data, we adjusted for cross-country differences using data on health expenditures per capita
from the World Bank database and adjusted to account for inflation. In addition, for each
country we assumed a fixed annual growth rate of the per capita treatment costs to adjust
for rising medical costs. The annual growth rate of the per capita health expenditure from
2005 to 2014 approximates this number, which is 13.4% for China, 4.6% for Japan, and
7.8% for South Korea. The treatment cost estimates in 2010 are listed in Table A2 in the
Appendix. The GDP projections for the status quo scenario are taken from the World
Bank’s Global Economic Prospects (2017).
Table 1 describes other data sources, while we show disease-specific estimates (ischemic
heart disease, cerebrovascular disease, diabetes, chronic obstructive pulmonary disease,
and breast cancer, before scaling) for each % of disease prevalence averted for each country
in Figure 2 (China), Figure 3 (Japan), and Figure 4 (South Korea). Table 2 shows disease-
specific burden as well as scaled estimates of the total disease burden (100% of mortality
averted for cardiovascular diseases, cancer, chronic respiratory diseases, diabetes, and
mental health conditions) for the period 2010-2030.
Table 1: Parameter Values and Data Sources
Parameter Value Source
α 1/3 e.g., Jones (1995)
δ 0.04-0.05 e.g., Grossmann et al. (2013)
s Depends on the country World Bank (2015)
η1 0.134 Psacharopoulos (1994), Hall and Jones (1999)
η2 0.101 Psacharopoulos (1994), Hall and Jones (1999)
η3 0.068 Psacharopoulos (1994), Hall and Jones (1999)
η4 0.09-0.132 Heckman et al. (2006)
η5 -0.0023 to -0.0013 Heckman et al. (2006)
ξi Depends on the country Institute for Health Metrics and Evaluation (2013)
χi Depends on the country Calculated through other parameters
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Figure 2: Differential GDP Associated with Averted Disease Prevalence for China (in
billions of 2010 USD)
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Figures 2-4 display, by disease, the estimated economic cost savings for a given percentage
of prevalence averted. For example, the estimate at 10% compares the cumulative differ-
ence in GDP in that country between the status quo scenario with disease prevalence as
predicted and the counterfactual scenario, where disease prevalence is reduced by 10%.
Results are shown in billions of real USD with a base year of 2010 and are cumulative over
the period of interest (2010-2030). These estimates indicate that the most costly condi-
tion varies by country, although breast cancer is generally the least costly. For example, in
China the most costly condition is cerebrovascular disease, and in Japan and South Korea
it is diabetes. Interestingly, COPD is expected to cost China 1.7 trillion USD over the
two decades. This is roughly 10.4% of China’s total NCD loss, compared with only 3.1%
in Japan and 5.1% in South Korea. The high prevalence of COPD in China is related to
its air pollution and the large fraction of its population that smokes. Overall, the ranking
of the impact of the other non-communicable diseases varies among the three countries.
We observe that the cost estimates increase roughly linearly with disease prevalence
averted. This linearity is not surprising because (19) is a good approximation of the
loss in labour supply given that the mortality related to each disease is small. Another
feature apparent from these figures is that the burden of non-communicable diseases is
much lower in South Korea than in the other two countries.
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Figure 3: Differential GDP Associated with Averted Disease Prevalence for Japan (in
billions of 2010 USD)
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The final row of Table 2 shows the estimates of the total impact of non-communicable
diseases in the five domains (cardiovascular diseases, cancer, chronic respiratory diseases,
diabetes, and mental health conditions), after the estimates for the individual diseases
have been scaled. Estimates are again given in real USD with a base year of 2010 for the
period 2010-2030. The results indicate that the total economic costs of chronic conditions
are 16 trillion USD in China, 5.7 trillion USD in Japan, and 1.5 trillion USD in South
Korea.
Table 2: Estimates of Total Disease Burden 2010-2030 (100% of Prevalence Averted) in
2010 USD (Billions)
Disease China Japan South Korea
Ischemic Heart Disease 1,140 534 119
Cerebrovascular Disease 1,728 555 145
Diabetes 1,333 667 280
COPD 1,681 177 77
Breast Cancer 213 77 12
Total (Including Mental Health Conditions) 16,190 5,707 1,511
As previous estimates using the production function-based approach have not included
the treatment cost mechanism, we investigate the contribution of this pathway to our
estimates of the total disease burden. Table A3 in the Appendix shows model estimates in
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Figure 4: Differential GDP Associated with Averted Disease Prevalence for South Korea
(in billions of 2010 USD)
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which we exclude treatment costs, and we use these results to establish the contribution
of treatment costs to the overall total in Figure 5. For China, treatment costs account for
64% of the costs of NCDs, while the corresponding figure is 33% for Japan and 37% for
South Korea. The relatively higher contribution of treatment costs in China can partly
be explained by its large gross savings rate (around 50% according to the World Bank),
compared with that of Japan (22%) and that of South Korea (35%). In our model, χ in
Equation (6) is approximated by the savings rate. A higher savings rate means that a
larger proportion of resources used in treatment could otherwise be used as investment
in physical capital. This leads to a larger output loss for countries with a higher savings
rate.
Our calculations highlight the importance of incorporating the treatment cost mechanism
as an additional pathway into the model for estimating the economic impact of chronic
conditions. Differences in the relative contribution of this pathway are likely due to het-
erogeneity in the prevalence of different conditions and country-specific factors relating to
health care systems.
One question that our analysis raises is whether considering the total costs associated
with NCDs as measured by reducing their prevalence to zero is reasonable. To get an
estimate of the total economic burden of certain conditions, this is indeed what we would
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like to know. However, when assessing the impact of realistic reductions in prevalence
that health policies can achieve, considering a scenario in which a particular disease is
eliminated is not reasonable. Chronic conditions may persist even under an ideal health
care system, and even technological advances might not be sufficient to reduce prevalence
to zero. Therefore, we also consider the costs associated with NCDs in a scenario where
we calculate the reduction in mortality for each disease such that the corresponding case
fatality rate reaches the minimum among OECD countries. For example, for China we
estimate how much COPD mortality would have to be reduced to ensure that China had
the same COPD-related case fatality rate (the proportion of reported cases of a specific
disease that are fatal within a specified time frame) as the OECD country with the lowest
COPD-related case fatality rate. The rationale for this analysis is that such a reduction is
a realistic target because another country has already achieved it. More specifically, the
lowest case fatality rates for ischemic heart disease, COPD, and cerebrovascular diseases
are set to those in Slovenia, Estonia, and Slovakia, respectively. For breast cancer and
diabetes the lowest levels are set to those in Cyprus and Iceland.9 The estimates are shown
in Table 3 and, while lower than those presented in Table 2, indicate that reasonable targets
for reductions in the prevalence of chronic conditions are likely to have substantial payoffs
in terms of reducing the costs associated with NCDs.
Figure 5: % Contribution of Treatment Costs to Total Estimate
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Finally, Table 4 provides the estimate of the total disease burden for different measures of
9Estimated case fatality rates were calculated by the authors based on 2015 disease incidence and
mortality rates from Global Burden of Disease Study (2015).
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Table 3: Estimated Economic Burdens Assuming the Case Fatality Rates of the Countries
with the Lowest Case Fatality Rates among OECD Countries
Country
Ischemic
Heart Disease
Cerebrovascular
Disease
Diabetes COPD
Breast
Cancer
Total Cost
China
Mortality Reduction (%)
Under the Assumption
29% 18% 29% 59% 44%
6,301
Burden of Excess Mortality
Billions (2010 USD)
328 302 383 977 94
Japan
Mortality Reduction (%)
Under the Assumption
52% 33% 37% 50% 14%
1,667
Burden of Excess Mortality
Billions (2010 USD)
274 181 249 88 11
South
Korea
Mortality Reduction (%)
Under the Assumption
36% 27% 66% 36% 10%
502
Burden of Excess Mortality
Billions (2010 USD)
42 39 184 28 1
economic performance. The total disease burden of NCDs (100% reduction), if measured
as a percentage of aggregate GDP in 2010, is largest in China with 265%, followed by
South Korea with 139%, and Japan with 100%. This measure, albeit straightforward, is
biased in that it leads to a larger proportional burden for countries with a higher growth
potential. Thus, the result is partly explained by the fact that China is expected to enjoy
a much higher GDP growth rate than Japan and South Korea. The per capita figures10
show that Japan has the highest NCD burden with a per capita loss of $44,562 (constant
USD with the base year 2010), compared with only $12,099 in China and $30,560 in South
Korea. Because Japan has the highest per capita GDP and health expenditure, the cost
of each unit of mortality and morbidity is higher for the Japanese. The third measure in
Table 4 shows that the NCD burdens of the three countries are actually relatively similar
if adjusted for the income level (or GDP per capita) and for the growth potential. The
NCD burden is equivalent to an annual tax of 7.17% on the economy in China, whereas
the number is 4.46% for Japan and 5.24% for South Korea.
Table 4: Total Disease Burden for Different Measures of Economic Performance
Country % of 2010 GDP
Per Capita Loss
(2010 USD)
% of Total GDP
During 2010-2030
Estimates Associated with
100% Reduction
of Disease Burden
China 265% 12,099 7.17%
Japan 100% 44,562 4.46%
South Korea 139% 30,560 5.24%
Estimates Associated with
Lowest Case Fatality Rate
among OECD Countries
China 103% 4,709 2.79%
Japan 29% 13,016 1.30%
South Korea 46% 10,158 1.74%
While our model can be used to estimate the economic burden of non-communicable dis-
eases and to assess the reduction in the burden from implementing a specific intervention,
it is unrealistic to assume a certain percentage of mortality reduction is costless. By com-
10The per capita loss is calculated based on the population size as of 2010.
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paring the total savings and total intervention costs, policymakers would be able to make
better-informed decisions on which intervention is the most cost-beneficial. We adopted
the intervention cost data for China from a recent study (Wang et al., 2014) and take
ischemic heart disease as an example to compare different treatments and their costs for
this disease.
Table 5 lists interventions that reduce the mortality rate of ischemic heart diseases. Strat-
egy A1 uses four oral drugs (aspirin, beta-blockers, angiotensin-converting enzyme in-
hibitors, and statins) in patients with acute myocardial infarction (AMI). Strategy A2
uses clopidogrel in patients with AMI. Strategy B uses unfractionated heparin in patients
with non-ST-segment-elevation myocardial infarction (NSTEMI). Strategy C1 uses pri-
mary percutaneous coronary intervention (PCI) in tertiary hospitals and thrombolysis
with streptokinase in secondary hospitals in patients with ST-segment-elevation myocar-
dial infarction (STEMI). Strategy C2 uses primary PCI in all patients with STEMI, and
strategy C3 uses primary PCI in high-risk patients with NSTEMI in tertiary hospitals.
Table 5: Intervention Cost and Mortality Reduction for Different Interventions
Intervention Mortality Reduction
Per Capita Intervention Cost
(2010 USD)
Strategy A1 1.3% 0.040
Strategy A2 0.4% 0.073
Strategy B 0.3% 0.007
Strategy C1 4.9% 0.436
Strategy C2 7.2% 0.762
Strategy C3 0.4% 0.097
Table 6 shows the total savings and total intervention cost from 2010-2030 for each inter-
vention in Table 5. Five of the six interventions are cost-beneficial. Specifically, strategy
B has the highest benefit-cost ratio, followed by strategies A1, C1, C2, and A2. Imple-
menting strategy C3 is not cost-beneficial.
Table 6: Estimates of Total Savings and Total Intervention Cost for Different Interventions
in 2010 USD (Billions)
Intervention Mortality reduction Total Savings Total Intervention Cost Benefit-Cost Ratio
Strategy A1 1.3% 13.95 1.15 12.13
Strategy A2 0.4% 3.05 2.09 1.46
Strategy B 0.3% 3.27 0.19 17.21
Strategy C1 4.9% 46.83 12.40 3.78
Strategy C2 7.2% 66.36 21.66 3.06
Strategy C3 0.4% 2.56 2.77 0.92
In Table 7 we compare the incremental cost-effectiveness ratio (ICER) from (Wang et al.,
2014) with the benefit-cost ratios that we calculated. The thresholds recommended by
WHO-CHOICE were used to assess the degree of cost-effectiveness. An intervention is
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Table 7: Comparison between Cost-Benefit Analysis and Cost-Effectiveness Analysis
Intervention Benefit-Cost Ratio ICER (Cost per QALY Gained)
Strategy A1 12.13 $3,100
Strategy A2 1.46 $17,600
Strategy B 17.21 $2,800
Strategy C1 3.78 $9,000
Strategy C2 3.05 $10,700
Strategy C3 0.92 $23,400
deemed highly cost-effective if ICER is less than the nation’s GDP per capita, is deemed
moderately cost-effective if ICER is between 1 and 3 times GDP per capita, and is deemed
not cost-effective if ICER is larger than 3 times GDP per capita. The GDP per capita of
China in 2013 (adjusted by inflation) was $5,721 according to the World Bank.
From Table 7, we can conclude that the interventions rank the same for the cost benefit
analysis and for the cost-effectiveness analysis, while the cutoff levels differ. Strategies
A1 and B are highly cost-effective, C1 and C2 are moderately cost-effective, while A2
and C3 are not cost-effective. In our study, by contrast, all strategies except C3 are
cost-beneficial. This is because our calculation is different from cost-effectiveness analysis.
We not only take into account the health outcome, but also the economic impact. For
example, the saved treatment cost from one intervention can be used to invest in physical
capital accumulation. Overall, strategy B has the highest benefit-cost ratio, followed by
strategy A1. This means that implementing strategies A1 and B would save much more
money for China from 2010-2030 than they cost. While strategy A2 is less cost-beneficial
than these two, the monetary value saved from this intervention is still higher than the
total intervention cost. Finally, note that our results actually represent a lower bound of
the benefits because the utility value that individuals assign to a longer and healthier life
is not quantified and because general equilibrium repercussions and a feedback effect from
income growth on health are not considered.
5 Conclusions
We implement a macroeconomic production function-based approach to assess the eco-
nomic burden of non-communicable diseases. The advantage of this approach over alter-
natives is that we can account for economic adjustment mechanisms and spillover effects
on labour markets and for heterogeneous human capital accumulation associated with in-
creases in disease prevalence. Using a human capital augmented production function as
proposed by Lucas (1988), we incorporate morbidity and mortality effects into the model
and account for treatment costs. We apply our approach to calculate the economic impact
of non-communicable diseases for China, Japan, and South Korea, three countries facing
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rapid population ageing. Our results indicate that chronic conditions are likely to be very
costly in terms of lost output, with estimates of the total burden over the time period
2010-2030 on the order of 16, 5.7, and 1.5 trillion 2010 USD for China, Japan, and South
Korea, respectively. Though the losses differ significantly at both aggregate and per capita
levels, the NCD burdens of the three countries are actually quite similar after adjusting for
the growth potential and the income level. In this case the figures are 7.17%, 4.46%, and
5.24% of total GDP for China, Japan, and South Korea, respectively, during 2010-2030.
We also applied a cost-benefit analysis to a set of intervention strategies in China and
showed that the total savings from all interventions are high and five of six strategies are
cost-beneficial. This result implies that a broader range of interventions can be recom-
mended to policymakers from an economic perspective than from a pure cost-effectiveness
perspective.
Cross-country heterogeneity exists in the ranking of disease importance, which likely re-
flects differential exposure to risk factors, smoking patterns, and environmental pollution.
A more detailed analysis of these differences is an important topic for future research.
The main conclusion of the paper is that the economic burden associated with non-
communicable diseases in East Asia, as elsewhere, is substantial. Efforts to tackle the
spread of chronic conditions and their associated risk factors now are likely to have sub-
stantial pay-offs in the future.
This model is flexible and could also be used to explore the impact of other factors im-
pinging on health such as communicable diseases and road-traffic accidents. In addition,
our approach is also relevant for modelling the impact of other health domains, such as
communicable diseases. In this paper we have stayed within the production function-based
framework, which has the advantages of i) providing a tractable and parsimonious method
for analysing the economic burden of chronic conditions and ii) leading to a conservative
estimate of the economic burden of diseases. This framework lays the ground for the
development of a micro-founded computable general equilibrium model in future research.
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Appendix: Additional results
Table A1: Data Sources of Treatment Costs
Disease Treatment Cost Source
Ischemic Heart Disease Chang et al. (2012)
Cerebrovascular Disease Lim et al. (2009)
Diabetes International Diabetes Federation (2015)
COPD Nishimura and Zaher (2004)
Breast Cancer Kim et al. (2008)
Table A2: Estimates of Treatment Cost per Country (2010 USD)
Country Disease Treatment Cost per Capita (in 2010 USD)
China Ischemic Heart Disease $13.29
Japan Ischemic Heart Disease $69.39
Korea Ischemic Heart Disease $29.23
China Cerebrovascular Disease $12.97
Japan Cerebrovascular Disease $67.76
Korea Cerebrovascular Disease $28.54
China Diabetes $11.62
Japan Diabetes $242.96
Korea Diabetes $154.45
China COPD $13.32
Japan COPD $69.94
Korea COPD $26.74
China Breast Cancer $2.78
Japan Breast Cancer $15.68
Korea Breast Cancer $4.91
Table A3: Estimates Excluding Treatment Costs in 2010 USD (Billions)
Disease China Japan Korea
Ischemic Heart Disease 388 428 90
Cerebrovascular Disease 993 452 117
Diabetes 268 243 128
COPD 926 74 51
Breast Cancer 55 53 7
Total (Including Mental Health Conditions) 5,781 3,775 943
30
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ICT 
26-2011 Marcus Müller, 
Guillaume Stern, 
Ansger Jacob and 
Stefan Kirn 
 
VERHALTENSMODELLE FÜR SOFTWAREAGENTEN IM  
PUBLIC GOODS GAME 
 
 
ICT 
27-2011 Monnet Benoit, 
Patrick Gbakoua and 
Alfonso Sousa-Poza  
ENGEL CURVES, SPATIAL VARIATION IN PRICES AND 
DEMAND FOR COMMODITIES IN CÔTE D’IVOIRE 
 
 
ECO 
28-2011 Nadine Riedel, 
Hannah Schildberg-
Hörisch 
 
ASYMMETRIC OBLIGATIONS 
 
 
ECO 
29-2011 Nicole Waidlein 
 
CAUSES OF PERSISTENT PRODUCTIVITY DIFFERENCES IN 
THE WEST GERMAN STATES IN THE PERIOD FROM 1950 TO 
1990 
 
IK 
30-2011 Dominik Hartmann, 
Atilio Arata 
 
MEASURING SOCIAL CAPITAL AND INNOVATION IN POOR 
AGRICULTURAL COMMUNITIES. THE CASE OF CHÁPARRA - 
PERU 
 
IK 
31-2011 Peter Spahn DIE WÄHRUNGSKRISENUNION 
DIE EURO-VERSCHULDUNG DER NATIONALSTAATEN ALS 
SCHWACHSTELLE DER EWU 
 
ECO 
32-2011 Fabian Wahl 
 
DIE ENTWICKLUNG DES LEBENSSTANDARDS IM DRITTEN 
REICH – EINE GLÜCKSÖKONOMISCHE PERSPEKTIVE 
 
ECO 
33-2011 Giorgio Triulzi, 
Ramon Scholz and 
Andreas Pyka 
 
R&D AND KNOWLEDGE DYNAMICS IN UNIVERSITY-INDUSTRY 
RELATIONSHIPS IN BIOTECH AND PHARMACEUTICALS: AN 
AGENT-BASED MODEL 
IK 
34-2011 Claus D. Müller-
Hengstenberg, 
Stefan Kirn 
 
ANWENDUNG DES ÖFFENTLICHEN VERGABERECHTS AUF 
MODERNE IT SOFTWAREENTWICKLUNGSVERFAHREN 
ICT 
35-2011 Andreas Pyka AVOIDING EVOLUTIONARY INEFFICIENCIES 
IN INNOVATION NETWORKS 
 
IK 
36-2011 David Bell, Steffen 
Otterbach and 
Alfonso Sousa-Poza 
 
WORK HOURS CONSTRAINTS AND HEALTH 
 
HCM 
37-2011 Lukas Scheffknecht, 
Felix Geiger 
A BEHAVIORAL MACROECONOMIC MODEL WITH  
ENDOGENOUS BOOM-BUST CYCLES AND LEVERAGE 
DYNAMICS 
 
ECO 
38-2011 Yin Krogmann,  
Ulrich Schwalbe 
 
INTER-FIRM R&D NETWORKS IN THE GLOBAL 
PHARMACEUTICAL BIOTECHNOLOGY INDUSTRY DURING 
1985–1998: A CONCEPTUAL AND EMPIRICAL ANALYSIS  
 
IK 
 
Nr. Autor Titel CC 
 
39-2011 
 
Michael Ahlheim, 
Tobias Börger and  
Oliver Frör 
 
 
RESPONDENT INCENTIVES IN CONTINGENT VALUATION: THE 
ROLE OF RECIPROCITY 
 
    ECO 
40-2011 Tobias Börger  
 
A DIRECT TEST OF SOCIALLY DESIRABLE RESPONDING IN 
CONTINGENT VALUATION INTERVIEWS 
 
    ECO 
41-2011 Ralf Rukwid,  
Julian P. Christ 
 
QUANTITATIVE CLUSTERIDENTIFIKATION AUF EBENE 
DER DEUTSCHEN STADT- UND LANDKREISE (1999-2008) 
    IK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nr. Autor Titel CC 
    
42-2012 Benjamin Schön,  
Andreas Pyka 
 
A TAXONOMY OF INNOVATION NETWORKS IK 
 
43-2012 Dirk Foremny, 
Nadine Riedel 
 
BUSINESS TAXES AND THE ELECTORAL CYCLE        ECO 
44-2012 Gisela Di Meglio, 
Andreas Pyka and 
Luis Rubalcaba 
 
VARIETIES OF SERVICE ECONOMIES IN EUROPE        IK 
45-2012 Ralf Rukwid,  
Julian P. Christ 
INNOVATIONSPOTENTIALE IN BADEN-WÜRTTEMBERG: 
PRODUKTIONSCLUSTER IM BEREICH „METALL, ELEKTRO, IKT“ 
UND REGIONALE VERFÜGBARKEIT AKADEMISCHER 
FACHKRÄFTE IN DEN MINT-FÄCHERN 
 
IK 
46-2012 Julian P. Christ,  
Ralf Rukwid 
INNOVATIONSPOTENTIALE IN BADEN-WÜRTTEMBERG: 
BRANCHENSPEZIFISCHE FORSCHUNGS- UND 
ENTWICKLUNGSAKTIVITÄT, REGIONALES 
PATENTAUFKOMMEN UND BESCHÄFTIGUNGSSTRUKTUR 
 
       IK 
47-2012 Oliver Sauter ASSESSING UNCERTAINTY IN EUROPE AND THE 
US - IS THERE A COMMON FACTOR? 
       ECO 
48-2012 Dominik Hartmann SEN MEETS SCHUMPETER. INTRODUCING STRUCTURAL AND 
DYNAMIC ELEMENTS INTO THE HUMAN CAPABILITY 
APPROACH 
 
       IK 
49-2012 Harold Paredes-
Frigolett,  
Andreas Pyka 
 
DISTAL EMBEDDING AS A TECHNOLOGY INNOVATION 
NETWORK FORMATION STRATEGY 
       IK 
50-2012 Martyna Marczak, 
Víctor Gómez 
CYCLICALITY OF REAL WAGES IN THE USA AND GERMANY: 
NEW INSIGHTS FROM WAVELET ANALYSIS 
       ECO 
51-2012 André P. Slowak DIE DURCHSETZUNG VON SCHNITTSTELLEN 
IN DER STANDARDSETZUNG: 
FALLBEISPIEL LADESYSTEM ELEKTROMOBILITÄT 
       IK 
 
52-2012 
 
Fabian Wahl 
 
WHY IT MATTERS WHAT PEOPLE THINK - BELIEFS, LEGAL 
ORIGINS AND THE DEEP ROOTS OF TRUST 
        
ECO 
 
53-2012 
 
Dominik Hartmann, 
Micha Kaiser 
 
STATISTISCHER ÜBERBLICK DER TÜRKISCHEN MIGRATION IN 
BADEN-WÜRTTEMBERG UND DEUTSCHLAND 
        
IK 
 
54-2012 
 
Dominik Hartmann, 
Andreas Pyka, Seda 
Aydin, Lena Klauß, 
Fabian Stahl, Ali 
Santircioglu, Silvia 
Oberegelsbacher, 
Sheida Rashidi, Gaye 
Onan and Suna 
Erginkoç 
 
IDENTIFIZIERUNG UND ANALYSE DEUTSCH-TÜRKISCHER 
INNOVATIONSNETZWERKE. ERSTE ERGEBNISSE DES TGIN-
PROJEKTES 
        
IK 
 
55-2012 
 
Michael Ahlheim, 
Tobias Börger and 
Oliver Frör 
 
THE ECOLOGICAL PRICE OF GETTING RICH IN A GREEN 
DESERT: A CONTINGENT VALUATION STUDY IN RURAL 
SOUTHWEST CHINA 
 
 
        
ECO 
Nr. Autor Titel CC 
 
56-2012 
 
Matthias Strifler 
Thomas Beissinger 
 
FAIRNESS CONSIDERATIONS IN LABOR UNION WAGE 
SETTING – A THEORETICAL ANALYSIS 
        
ECO 
 
57-2012 
 
Peter Spahn 
 
INTEGRATION DURCH WÄHRUNGSUNION? 
DER FALL DER EURO-ZONE 
        
ECO 
 
58-2012 
 
Sibylle H. Lehmann 
 
TAKING FIRMS TO THE STOCK MARKET:  
IPOS AND THE IMPORTANCE OF LARGE BANKS IN IMPERIAL 
GERMANY 1896-1913 
        
ECO 
 
59-2012 Sibylle H. Lehmann, 
Philipp Hauber and 
Alexander Opitz 
 
POLITICAL RIGHTS, TAXATION, AND FIRM VALUATION – 
EVIDENCE FROM SAXONY AROUND 1900 
ECO        
 
60-2012 Martyna Marczak, 
Víctor Gómez 
SPECTRAN, A SET OF MATLAB PROGRAMS FOR SPECTRAL 
ANALYSIS 
ECO        
 
61-2012 Theresa Lohse, 
Nadine Riedel 
THE IMPACT OF TRANSFER PRICING REGULATIONS ON 
PROFIT SHIFTING WITHIN EUROPEAN MULTINATIONALS 
ECO        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Nr. Autor Titel CC 
 
62-2013 Heiko Stüber REAL WAGE CYCLICALITY OF NEWLY HIRED WORKERS ECO        
 
63-2013 David E. Bloom, 
Alfonso Sousa-Poza 
AGEING AND PRODUCTIVITY HCM 
 
64-2013 Martyna Marczak, 
Víctor Gómez 
MONTHLY US BUSINESS CYCLE INDICATORS: 
A NEW MULTIVARIATE APPROACH BASED ON A BAND-PASS 
FILTER 
 
ECO 
 
65-2013 Dominik Hartmann, 
Andreas Pyka 
INNOVATION, ECONOMIC DIVERSIFICATION AND HUMAN 
DEVELOPMENT 
IK 
 
66-2013 Christof Ernst, 
Katharina Richter and 
Nadine Riedel 
CORPORATE TAXATION AND THE QUALITY OF RESEARCH 
AND DEVELOPMENT 
ECO 
 
 
67-2013 Michael Ahlheim, 
Oliver Frör, Jiang 
Tong, Luo Jing and 
Sonna Pelz 
 
NONUSE VALUES OF CLIMATE POLICY - AN EMPIRICAL STUDY 
IN XINJIANG AND BEIJING 
ECO 
 
68-2013 Michael Ahlheim, 
Friedrich Schneider 
CONSIDERING HOUSEHOLD SIZE IN CONTINGENT VALUATION 
STUDIES 
ECO 
 
69-2013 Fabio Bertoni,  
Tereza Tykvová 
WHICH FORM OF VENTURE CAPITAL IS MOST SUPPORTIVE 
OF INNOVATION? 
EVIDENCE FROM EUROPEAN BIOTECHNOLOGY COMPANIES 
 
CFRM 
 
70-2013 Tobias Buchmann, 
Andreas Pyka  
THE EVOLUTION OF INNOVATION NETWORKS: 
THE CASE OF A GERMAN AUTOMOTIVE NETWORK 
IK 
 
71-2013 B. Vermeulen, A. 
Pyka, J. A. La Poutré 
and A. G. de Kok  
CAPABILITY-BASED GOVERNANCE PATTERNS OVER THE 
PRODUCT LIFE-CYCLE 
IK 
 
 
72-2013 
 
Beatriz Fabiola López 
Ulloa, Valerie Møller 
and Alfonso Sousa-
Poza   
 
HOW DOES SUBJECTIVE WELL-BEING EVOLVE WITH AGE?  
A LITERATURE REVIEW 
 
HCM 
 
 
73-2013 
 
Wencke Gwozdz, 
Alfonso Sousa-Poza, 
Lucia A. Reisch, 
Wolfgang Ahrens, 
Stefaan De Henauw, 
Gabriele Eiben, Juan 
M. Fernández-Alvira, 
Charalampos 
Hadjigeorgiou, Eva 
Kovács, Fabio Lauria, 
Toomas Veidebaum, 
Garrath Williams, 
Karin Bammann 
 
MATERNAL EMPLOYMENT AND CHILDHOOD OBESITY – 
A EUROPEAN PERSPECTIVE 
 
HCM 
 
 
 
 
 
Nr. Autor Titel CC 
 
74-2013 
 
Andreas Haas, 
Annette Hofmann  
 
 
RISIKEN AUS CLOUD-COMPUTING-SERVICES: 
FRAGEN DES RISIKOMANAGEMENTS UND ASPEKTE DER 
VERSICHERBARKEIT 
 
HCM 
 
 
75-2013 
 
Yin Krogmann, 
Nadine Riedel and 
Ulrich Schwalbe  
 
 
INTER-FIRM R&D NETWORKS IN PHARMACEUTICAL 
BIOTECHNOLOGY: WHAT DETERMINES FIRM’S 
CENTRALITY-BASED PARTNERING CAPABILITY? 
 
ECO, IK 
 
 
76-2013 
 
Peter Spahn 
 
MACROECONOMIC STABILISATION AND BANK LENDING: 
A SIMPLE WORKHORSE MODEL 
 
ECO 
 
 
77-2013 
 
Sheida Rashidi, 
Andreas Pyka 
 
MIGRATION AND INNOVATION – A SURVEY 
 
IK 
 
 
78-2013 
 
Benjamin Schön, 
Andreas Pyka 
 
THE SUCCESS FACTORS OF TECHNOLOGY-SOURCING 
THROUGH MERGERS & ACQUISITIONS – AN INTUITIVE META-
ANALYSIS 
 
IK 
 
 
79-2013 
 
Irene Prostolupow, 
Andreas Pyka and 
Barbara Heller-Schuh 
 
TURKISH-GERMAN INNOVATION NETWORKS IN THE 
EUROPEAN RESEARCH LANDSCAPE 
 
IK 
 
 
80-2013 
 
Eva Schlenker, 
Kai D. Schmid 
 
CAPITAL INCOME SHARES AND INCOME 
INEQUALITY IN THE EUROPEAN UNION 
 
       ECO 
 
81-2013 Michael Ahlheim, 
Tobias Börger and 
Oliver Frör 
THE INFLUENCE OF ETHNICITY AND CULTURE ON THE 
VALUATION OF ENVIRONMENTAL IMPROVEMENTS 
– RESULTS FROM A CVM STUDY IN SOUTHWEST CHINA – 
       ECO 
 
82-2013 
 
Fabian Wahl DOES MEDIEVAL TRADE STILL MATTER? HISTORICAL TRADE 
CENTERS, AGGLOMERATION AND CONTEMPORARY 
ECONOMIC DEVELOPMENT 
       ECO 
 
83-2013 Peter Spahn SUBPRIME AND EURO CRISIS: SHOULD WE BLAME THE 
ECONOMISTS? 
       ECO 
 
84-2013 Daniel Guffarth, 
Michael J. Barber 
THE EUROPEAN AEROSPACE R&D COLLABORATION 
NETWORK 
       IK 
 
85-2013 Athanasios Saitis KARTELLBEKÄMPFUNG UND INTERNE KARTELLSTRUKTUREN: 
EIN NETZWERKTHEORETISCHER ANSATZ 
       IK 
 
 
 
 
 
 
 
 
 
Nr. Autor Titel CC 
 
86-2014 Stefan Kirn, Claus D. 
Müller-Hengstenberg 
INTELLIGENTE (SOFTWARE-)AGENTEN: EINE NEUE 
HERAUSFORDERUNG FÜR DIE GESELLSCHAFT UND UNSER 
RECHTSSYSTEM? 
 
ICT       
 
87-2014 Peng Nie, Alfonso 
Sousa-Poza 
MATERNAL EMPLOYMENT AND CHILDHOOD OBESITY IN 
CHINA: EVIDENCE FROM THE CHINA HEALTH AND NUTRITION 
SURVEY 
 
HCM        
 
88-2014 Steffen Otterbach, 
Alfonso Sousa-Poza 
JOB INSECURITY, EMPLOYABILITY, AND HEALTH: 
AN ANALYSIS FOR GERMANY ACROSS GENERATIONS 
HCM        
 
89-2014 Carsten Burhop, 
Sibylle H. Lehmann-
Hasemeyer 
 
THE GEOGRAPHY OF STOCK EXCHANGES IN IMPERIAL 
GERMANY 
ECO        
 
90-2014 Martyna Marczak, 
Tommaso Proietti 
OUTLIER DETECTION IN STRUCTURAL TIME SERIES 
MODELS: THE INDICATOR SATURATION APPROACH 
ECO        
 
91-2014 Sophie Urmetzer, 
Andreas Pyka 
VARIETIES OF KNOWLEDGE-BASED BIOECONOMIES IK        
 
92-2014 Bogang Jun,  
Joongho Lee 
THE TRADEOFF BETWEEN FERTILITY AND EDUCATION:  
EVIDENCE FROM THE KOREAN DEVELOPMENT PATH 
IK        
 
93-2014 Bogang Jun,  
Tai-Yoo Kim 
NON-FINANCIAL HURDLES FOR HUMAN CAPITAL 
ACCUMULATION: LANDOWNERSHIP IN KOREA UNDER 
JAPANESE RULE 
 
IK        
 
94-2014 Michael Ahlheim, 
Oliver Frör, 
Gerhard 
Langenberger and 
Sonna Pelz  
 
CHINESE URBANITES AND THE PRESERVATION OF RARE 
SPECIES IN REMOTE PARTS OF THE COUNTRY – THE 
EXAMPLE OF EAGLEWOOD 
ECO        
 
95-2014 Harold Paredes-
Frigolett, 
Andreas Pyka, 
Javier Pereira and 
Luiz Flávio Autran 
Monteiro Gomes 
 
RANKING THE PERFORMANCE OF NATIONAL INNOVATION 
SYSTEMS IN THE IBERIAN PENINSULA AND LATIN AMERICA 
FROM A NEO-SCHUMPETERIAN ECONOMICS PERSPECTIVE 
IK        
 
96-2014 Daniel Guffarth, 
Michael J. Barber 
 
NETWORK EVOLUTION, SUCCESS, AND REGIONAL 
DEVELOPMENT IN THE EUROPEAN AEROSPACE INDUSTRY 
IK        
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